Want to see LUCD full AI Analyst Report?
LUCD Stock Chart & Stats
$0.91
<$0.01(0.26%)
At close: 4:00 PM EDT
$0.91
<$0.01(0.26%)
Day’s Range― - ―
52-Week Range$0.86 - $1.63
Previous CloseN/A
Volume689.08K
Average Volume (3M)1.86M
Market Cap
$183.00M
Enterprise Value$170.17
Total Cash (Recent Filing)$27.88M
Total Debt (Recent Filing)$26.80M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Aug 13, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding203,066,790
10 Day Avg. Volume1,959,284
30 Day Avg. Volume1,861,430
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)10.16
Price to Sales (P/S)23.61
P/FCF Ratio-2.39
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.95Price Target Upside334.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.24
Revenue Forecast (FY)$7.38M
Bulls Say, Bears Say
Bulls Say
Test VolumeConsistent test volume above the company’s pre‑Medicare target shows durable commercial adoption and clinical demand. Sustained procedure throughput supports lab utilization, provider familiarity, and a scalable revenue base that can compound if reimbursement rates normalize and distribution expands.
Balance Sheet RunwayA meaningful equity raise materially extends runway, giving management time to execute commercialization initiatives and pursue payer coverage. This reduces immediate financing pressure and enables investment in sales, clinical studies, and operations that are necessary to convert volume into sustainable revenue.
Payer & Guideline MomentumSecuring LBM coverage, plus VA FSS placement and favorable guideline mention, creates structural distribution and reimbursement catalysts. These represent durable advances in payor engagement that can accelerate coverage adoption and reduce dependence on ad‑hoc payer decisions over subsequent quarters.
Bears Say
Negative Gross ProfitNegative gross margins indicate the core test currently loses money on a unit basis, making scale alone insufficient to restore profitability. Persistent loss on sales undermines margin sustainability and requires either pricing/reimbursement improvements or material cost reductions to achieve lasting operating leverage.
High LeverageA heavily debt‑loaded capital structure creates durable financial risk: elevated interest expense, refinancing vulnerability, and limited flexibility to absorb commercialization setbacks. High leverage constrains strategic options and increases the likelihood of future dilutive financing if revenue and collections underperform.
Reimbursement & Collections RiskSevere reimbursement and adjudication uncertainty materially reduces convertibility of billable tests into recognized revenue and cash. Reliance on Medicare LCD outcomes and volatile payer decisions creates a structural gating item: until payors broadly accept the test, cash flow and revenue visibility remain impaired.
Lucid Diagnostics News
LUCD FAQ
What was Lucid Diagnostics’s price range in the past 12 months?
Lucid Diagnostics lowest stock price was $0.86 and its highest was $1.63 in the past 12 months.
What is Lucid Diagnostics’s market cap?
Lucid Diagnostics’s market cap is $183.00M.
When is Lucid Diagnostics’s upcoming earnings report date?
Lucid Diagnostics’s upcoming earnings report date is Aug 13, 2026 which is in 11 days.
How were Lucid Diagnostics’s earnings last quarter?
Lucid Diagnostics released its earnings results on May 14, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.063 by -$0.007.
Is Lucid Diagnostics overvalued?
According to Wall Street analysts Lucid Diagnostics’s price is currently Undervalued.
Does Lucid Diagnostics pay dividends?
Lucid Diagnostics does not currently pay dividends.
What is Lucid Diagnostics’s EPS estimate?
Lucid Diagnostics’s EPS estimate is -0.05.
How many shares outstanding does Lucid Diagnostics have?
Lucid Diagnostics has 203,066,790 shares outstanding.
What happened to Lucid Diagnostics’s price movement after its last earnings report?
Lucid Diagnostics reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.063. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lucid Diagnostics?
Currently, no hedge funds are holding shares in LUCD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lucid Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.95 (334.07% Upside)
$3.95 (334.07% Upside)
Blogger Sentiment
Bullish
LUCD Sentiment 100%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 29.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $245.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.92%
Trailing 12-Months
Company Description
Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
LUCD Company Deck
LUCD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mix of constructive commercial and balance-sheet progress (test volume above targets, LBM policy secured, VA contract and initial PO, strengthened pro forma cash position, favorable draft guideline mention) alongside material near-term reimbursement and collection challenges (Medicare LCD delays, conservative revenue recognition practices, adjudication volatility and denials, elevated burn rate). Management expressed confidence and has positioned to scale once Medicare coverage is issued, but the company currently faces meaningful timing and cash-collection risk that keeps fundamentals mixed.View all LUCD earnings summariesLUCD Stock 12 Month Forecast
Average Price Target
$3.95
▲(334.07% Upside)
Technical Analysis
Ownership Overview
5.36% Insiders
3.77% Mutual Funds
0.82% Other Institutional Investors
83.50% Public Companies and
Individual Investors